CUE HEALTH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.146 USD | +3.55% |
|
+3.55% | -10.15% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,963 | 309.3 | 25.13 | 23.23 | - | - |
| Enterprise Value (EV) 1 | 1,559 | 71.01 | 25.13 | 2.107 | 6.646 | -25.05 |
| P/E ratio | - | - | -0.07 x | -0.12 x | -0.2 x | -1.46 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.18 x | 0.64 x | 0.35 x | 0.41 x | 0.21 x | 0.11 x |
| EV / Revenue | 2.52 x | 0.15 x | 0.35 x | 0.04 x | 0.06 x | -0.12 x |
| EV / EBITDA | 7 x | -0.46 x | -0.12 x | -0.01 x | -0.05 x | 0.3 x |
| EV / FCF | -12,453,393 x | -438,039 x | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - |
| Price to Book | 2.78 x | 0.54 x | - | 0.33 x | 0.73 x | 0.66 x |
| Nbr of stocks (in thousands) | 146,363 | 149,432 | 154,632 | 159,092 | - | - |
| Reference price 2 | 13.41 | 2.070 | 0.1625 | 0.1460 | 0.1460 | 0.1460 |
| Announcement Date | 3/29/22 | 3/15/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 618.1 | 483.5 | 70.94 | 56.98 | 109.8 | 207.3 |
| EBITDA 1 | - | 222.7 | -155.8 | -212.6 | -170.2 | -142.3 | -82.86 |
| EBIT 1 | - | 190.2 | -200.8 | -268.8 | -225.4 | -179.5 | -109.9 |
| Operating Margin | - | 30.77% | -41.53% | -379% | -395.5% | -163.5% | -52.99% |
| Earnings before Tax (EBT) 1 | - | 119.2 | -203.8 | -368.7 | -223.9 | -170.1 | -42.03 |
| Net income 1 | -47.35 | 86.42 | - | -373.5 | -223.9 | -170.1 | -44.38 |
| Net margin | - | 13.98% | - | -526.48% | -392.96% | -154.91% | -21.4% |
| EPS 2 | -2.900 | - | - | -2.440 | -1.225 | -0.7400 | -0.1000 |
| Free Cash Flow | - | -125.2 | -162.1 | - | - | - | - |
| FCF margin | - | -20.25% | -33.53% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/19/21 | 3/29/22 | 3/15/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 223.7 | 192.5 | 179.4 | 87.7 | 69.59 | 146.8 | 24.76 | 9.896 | 17.48 | 18.8 | 10.1 | 9.55 | 13.41 | 25.16 | 25.8 |
| EBITDA | 118.9 | 29.81 | 13.45 | -46.71 | -52.85 | - | -83.79 | -64.57 | -49.3 | -34.57 | - | - | - | - | - |
| EBIT 1 | 87.38 | 23.38 | 2.848 | -57.69 | -64.26 | -81.68 | -95.85 | -85.39 | -64.7 | -49.79 | -57.47 | -54.74 | -52.83 | -51.81 | -47.6 |
| Operating Margin | 39.06% | 12.15% | 1.59% | -65.78% | -92.34% | -55.65% | -387.04% | -862.9% | -370.23% | -264.85% | -568.8% | -573.15% | -393.85% | -205.93% | -184.5% |
| Earnings before Tax (EBT) 1 | 49.45 | 23.62 | 2.803 | - | -67.35 | -36.82 | -94.2 | -83.86 | -42.24 | -148.4 | -53.1 | -51 | -50.1 | -51.3 | -46.5 |
| Net income 1 | 19.35 | 34.23 | 2.803 | - | -66.3 | -31.51 | -94.2 | -83.86 | -46.97 | -148.4 | -53.1 | -51 | -50.1 | -51.3 | -46.5 |
| Net margin | 8.65% | 17.78% | 1.56% | - | -95.28% | -21.47% | -380.37% | -847.45% | -268.75% | -789.62% | -525.59% | -534% | -373.48% | -203.91% | -180.23% |
| EPS 2 | 0.1300 | - | - | - | -0.4500 | -0.2100 | -0.6200 | -0.5500 | -0.3100 | -0.9600 | -0.3400 | -0.3300 | -0.3200 | -0.3300 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/29/22 | 5/11/22 | 8/10/22 | 11/9/22 | 3/15/23 | 5/10/23 | 8/9/23 | 11/8/23 | 3/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 404 | 238 | - | 21.1 | 16.6 | 48.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -125 | -162 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 28.6% | -30.2% | - | -124% | -149% | -46% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 4.830 | 3.830 | - | 0.4400 | 0.2000 | 0.2200 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 116 | 50.2 | - | - | - | - |
| Capex / Sales | - | 18.72% | 10.38% | - | - | - | - |
| Announcement Date | 4/19/21 | 3/29/22 | 3/15/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.146
USD
Average target price
0.75
USD
Spread / Average Target
+413.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.15% | 23.23M | |
| +6.97% | 2,990B | |
| +5.80% | 83.1B | |
| +3.72% | 76.88B | |
| -15.77% | 52.88B | |
| +32.96% | 50.84B | |
| -25.56% | 46.09B | |
| +17.43% | 41.3B | |
| +59.31% | 37.06B | |
| -10.36% | 24.61B |
- Stock Market
- Equities
- HLTH Stock
- Financials Cue Health Inc.
